Ardea Biosciences – “Astra Acquires Ardea – Lesinurad’s Opportunity Expands!”
Today’s announcement of an acquisition of Ardea Biosciences (RDEA) by AstraZeneca (AZN) for $32/s or ~$1.26b is the second deal in this month in the gout space, after Takeda (TYO: 4502) acquired privately-held US based, URL pharma. There is a major unmet medical need for a better treatment option for the majority of gout pts, who do not achieve adequate response to allopurinol (serum urate <6mg/dL) and Lesinurad (PhIII, URAT1 Inhibitor) has shown impressive efficacy in its earlier trial. For more details, please read our report released on 23rd April, 2012 on RDEA titled “Astra Acquires Ardea – Lesinurad’s Opportunity Expands”
COMPANIES MENTIONED
ARDEA
ARDEA
